Thulium Laser and Growth Factors for Androgenetic Alopecia

NCT07079657 · tracked via the Priya Life Science Germany tracker

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Phase

Not applicable

Started

2023-12-01

Last updated

2025-07-23

Condition(s) studied

Androgenetic Alopecia (AGA)

Investigational drug(s) / intervention(s)

Thulium laser + growth factor serum + LEDThulium laser + growth factor serumThulium laser

Thulium laser + growth factor serum + LED: 3 sessions at intervals of 6 weeks

Thulium laser + growth factor serum: 3 sessions at intervals of 6 weeks

Thulium laser: 3 sessions at intervals of 6 weeks

Study summary

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected.

Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity.

Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Men and women aged 18 and over * Good general health, no relevant previous illnesses * Presence of an AGA * Cognitive ability and willingness to give consent (informed consent) * Be willing and able to attend follow-up visits Exclusion Criteria: * Age \< 18 years * Pregnant or breastfeeding women * Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs * Significant scarring of the region to be treated * Significant open wounds or lesions in the region to be treated * Metallic implants in the head region * Mental illnesses (psychoses, body perception disorders) * Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks * Resurfacing (fractional, ablative, non-ablative) of the affected region \< 2 months before and during the study period * Tendency to excessive scarring * Lack of informed consent and/or data protection declarations

Primary outcome measure(s)

Subject Global Aesthetic Improvement Scale — 1 and 6 months post-treatment
scale from 0 (very much improved) to 4 (worse)
Hair density — at baseline, and 1 and 6 months post-treatment
measurement of hair density before and after treatment
hair thickness — at baseline, and 1 and 6 months post-treatment
hair thickness before and after treatment

Trial sites (1)

Facility	City	Region	Status
University Medical Center Hamburg-Eppendorf	Hamburg	Free and Hanseatic City of Hamburg	Recruiting

More Universitätsklinikum Hamburg-Eppendorf trials in Germany

External Validation of the MASCAN Score for the Classification of Difficult Mask Ventilation Recruiting

Characterisation of phenotYpes in aCute Heart faiLure patiEnts Recruiting

Prospective Registry and Biobank for Long-term Observational Studies in Adult Patients with Pulmonary Hypertension Recruiting

Proof of Concept Human Study: Dietary Intervention to Modify Intestinal Inflammation in IBD Active, not recruiting

Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07079657 on ClinicalTrials.gov ↗ ← All trials in Germany